tiprankstipranks
Trending News
More News >

Livzon Pharma Gains Approval for Innovative Schizophrenia Treatment

Story Highlights
Livzon Pharma Gains Approval for Innovative Schizophrenia Treatment

Confident Investing Starts Here:

The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).

Livzon Pharmaceutical Group Inc. announced the approval of its Aripiprazole Microspheres for Injection by the National Medical Products Administration. This long-acting, sustained-release medication is designed for adult schizophrenia treatment, offering a once-a-month administration that enhances medication adherence and reduces recurrence, hospitalization, and associated economic and social burdens.

More about Livzon Pharmaceutical Group

Livzon Pharmaceutical Group Inc. is a company operating in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in the creation of innovative drug formulations, with a market focus on addressing medical needs such as schizophrenia treatment.

Average Trading Volume: 957,325

Technical Sentiment Signal: Buy

Current Market Cap: HK$30.53B

Find detailed analytics on 1513 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App